Clene Inc (CLNN)

Over the past six months, Clene's stock has been impacted by several events. Disappointing Q3 2025 financial results in November 2025 led to a stock decline. Analysts anticipated a final loss in 2026 before profitability in 2027. Plans to update on the CNM-Au8 program in ALS caused a stock surge in December 2025. Benchmark reiterated a "Buy" rating after positive biomarker data for CNM-Au8. An oversubscribed registered direct offering exceeding $28 million to fund ALS treatment development was announced in January 2026. Additional CNM-Au8 biomarker data supported a potential NDA filing. A stockholder letter in February 2026 highlighted upcoming CNM-Au8 catalysts, including a planned NDA submission in Q2 2026. The stock price has decreased by 18.00% over the past six months, but as of February 27, 2026, the share price was $5.22, an increase of 20.67% from March 3, 2025.

Specific information regarding demand seasonality for Clene, Inc.'s products is not explicitly available. As a clinical-stage pharmaceutical company, its primary focus is on drug development and regulatory approval. While Clene markets dietary supplements, there is no specific data indicating seasonality in their demand. Stock price seasonality analysis suggests February and March may be ideal months for positive returns, reflecting stock market trends rather than direct product demand.

Clene, Inc. is a clinical-stage biopharmaceutical company focused on developing clean-surfaced nanotechnology (CSN) therapeutics for neurodegenerative diseases like ALS, Parkinson's Disease, and MS. Their core approach involves nanotherapeutics targeting cellular energy impairments. Clene also operates a segment for dietary supplements. Key products include CNM-Au8 (for ALS, MS, PD), CNM-AgZn17 (for infectious diseases and wound healing), CNM-ZnAg (antiviral and antibacterial agent), rMetx (zinc-silver ion dietary supplement), and KHC46 (gold dietary supplement). Clene is classified in the Consumer Defensive sector, Packaged Foods industry, and Biotechnology & Medical Research sector.

Clene Inc.'s corporate headquarters and development operations are located in Salt Lake City, Utah, United States. The company also has research and development (R&D) and manufacturing operations in Maryland, United States.

Clene Inc.'s brand reputation is influenced by the progress of CNM-Au8. Analysts generally maintain a positive outlook, with a consensus rating of "Strong Buy". Positive biomarker data for CNM-Au8 in ALS has been a key factor, leading to expectations of accelerated FDA approval. However, Clene faces financial challenges, including financial distress and a high risk of bankruptcy, which can impact investor reputation. The company's stock has also experienced volatility.

Clene Inc. has a mixed ownership structure. Institutional investors hold approximately 7.41% to 23.28% of the stock, with SymBiosis Capital Partners, LLC, and Scoggin Management Lp among the largest holders. Insiders own approximately 35.30% to 44.90% of the stock, with Jonathon Gay owning the most shares. Public companies and individual investors hold approximately 1.41% to 44.36% of the stock.